AT282630T - Dolastatin derivatives - Google Patents

Dolastatin derivatives

Info

Publication number
AT282630T
AT282630T AT94927086T AT94927086T AT282630T AT 282630 T AT282630 T AT 282630T AT 94927086 T AT94927086 T AT 94927086T AT 94927086 T AT94927086 T AT 94927086T AT 282630 T AT282630 T AT 282630T
Authority
AT
Austria
Prior art keywords
dolastatin derivatives
dolastatin
derivatives
Prior art date
Application number
AT94927086T
Other languages
German (de)
Inventor
Kyoichi Sakakibara
Masaaki Gondo
Koichi Miyazaki
Takeshi Ito
Akihiro Sugimura
Motohiro Kobayashi
Original Assignee
Teikoku Hormone Mfg Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP26964293 priority Critical
Application filed by Teikoku Hormone Mfg Co Ltd filed Critical Teikoku Hormone Mfg Co Ltd
Priority to PCT/JP1994/001560 priority patent/WO1995009864A1/en
Publication of AT282630T publication Critical patent/AT282630T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood
    • Y10S530/83Plasma; serum
AT94927086T 1993-10-01 1994-09-22 Dolastatin derivatives AT282630T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP26964293 1993-10-01
PCT/JP1994/001560 WO1995009864A1 (en) 1993-10-01 1994-09-22 Novel peptide derivative

Publications (1)

Publication Number Publication Date
AT282630T true AT282630T (en) 2004-12-15

Family

ID=17475197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927086T AT282630T (en) 1993-10-01 1994-09-22 Dolastatin derivatives

Country Status (10)

Country Link
US (2) US5767237A (en)
EP (1) EP0731106B1 (en)
JP (1) JP3469580B2 (en)
AT (1) AT282630T (en)
AU (1) AU689131B2 (en)
CA (1) CA2173150C (en)
DE (2) DE69434136T2 (en)
ES (1) ES2233928T3 (en)
SG (1) SG44794A1 (en)
WO (1) WO1995009864A1 (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3469580B2 (en) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 The novel peptide derivatives
WO1996033212A1 (en) * 1995-04-21 1996-10-24 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
GB9625895D0 (en) * 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7608681B2 (en) * 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1545613B9 (en) * 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
RU2448117C2 (en) * 2003-11-06 2012-04-20 Сиэтл Дженетикс, Инк. Monomethylvaline compounds capable of forming conjugates with ligands
CA2841741A1 (en) 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
WO2006041641A2 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Therapeutic agents with decreased toxicity
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1838660A2 (en) * 2005-01-13 2007-10-03 F. Hoffmann-Roche AG New one-step synthesis of useful disubstituted amines
EP1917020B1 (en) * 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
RS53168B (en) 2006-05-30 2014-06-30 Genentech Inc. Antibodies and immunoconjugates and uses therefor
KR20140116546A (en) 2006-10-27 2014-10-02 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
BRPI0806403A2 (en) 2007-02-09 2011-09-06 Genentech Inc anti-robo4 antibody, use an antibody and imaging method
TW200902554A (en) 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
EP2657253B1 (en) 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2176295B1 (en) * 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2176296T3 (en) * 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B antibodies and immune conjugates and methods of use.
RU2505544C2 (en) * 2007-10-19 2014-01-27 Дженентек, Инк. Antibodies against tenb2 constructed with cysteine, and conjugates, antibody-drug
JP5727786B2 (en) 2007-10-19 2015-06-03 シアトル ジェネティクス,インコーポレーテッド CD19 binding substance and use thereof
BRPI0907046A2 (en) 2008-01-18 2015-07-28 Medimmune Llc Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
BRPI1012676A2 (en) * 2009-04-01 2016-04-05 Genentech Inc anti-fcrh5 and immunoconjugate antibodies and methods of use
JP6099976B2 (en) 2009-04-01 2017-03-29 ジェネンテック, インコーポレイテッド Anti-FcRH5 antibodies and immunoconjugates and methods of use
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2577310B1 (en) 2010-06-03 2018-11-14 F.Hoffmann-La Roche Ag Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック, インコーポレイテッド Cysteine engineered antibodies and conjugates
DK3029066T3 (en) 2010-07-29 2019-05-20 Xencor Inc Antibodies with modified isoelectric items
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
AR084747A1 (en) 2010-12-30 2013-06-05 Takeda Pharmaceutical Anti-CD38 antibodies
US8685383B2 (en) 2011-06-10 2014-04-01 Mersana Therapeautics, Inc. Protein-polymer-drug conjugates
JP6334553B2 (en) 2012-12-10 2018-05-30 メルサナ セラピューティクス,インコーポレイティド Protein-polymer-drug conjugate
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
AU2012315956B2 (en) 2011-09-29 2016-01-21 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
CA2852860A1 (en) 2011-11-17 2013-05-23 Matthew David DOROSKI Cytotoxic peptides and antibody drug conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc Antibodies and immunoconjugates LGR5
CA2867824A1 (en) 2012-05-01 2013-11-07 Genentech, Inc. Anti-pmel17 antibodies and immunoconjugates
CN107982545A (en) 2012-05-15 2018-05-04 索伦托医疗有限公司 Drug conjugates, coupling method, and application thereof
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
KR20150105472A (en) 2013-01-14 2015-09-16 젠코어 인코포레이티드 Novel heterodimeric proteins
CA2902739A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CA2902865A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CA2906927A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (en) * 2013-04-25 2014-10-31 Pf Medicament Derivatives of dolastatin 10 and auristatines
AR096687A1 (en) 2013-06-24 2016-01-27 Genentech Inc Anti-fcrh5
MX2016003248A (en) 2013-09-17 2016-06-07 Genentech Inc Methods of using anti-lgr5 antibodies.
US10316080B2 (en) 2013-10-11 2019-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
DK3054991T3 (en) 2013-10-11 2019-05-06 Mersana Therapeutics Inc PROTEIN POLYMER-drug conjugates
EP3055331A1 (en) 2013-10-11 2016-08-17 Oxford Bio Therapeutics Limited Conjugated antibodies against ly75 for the treatment of cancer
EP3461845A1 (en) 2013-12-13 2019-04-03 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
CA2930614A1 (en) 2013-12-17 2015-06-25 Novartis Ag Cytotoxic peptides and conjugates thereof
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
PE14312016A1 (en) 2014-03-28 2017-01-22 Xencor Inc bispecific antibodies that bind to CD38 and CD3
BR112016024363A2 (en) 2014-04-25 2017-10-10 Pf Medicament antibody-drug conjugate and its use for cancer treatment
US9884817B2 (en) 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
CA2956178A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
TW201625689A (en) 2014-09-12 2016-07-16 Genentech Inc Anti -b7-h4 antibody and immune conjugate
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
KR20170069227A (en) 2014-09-17 2017-06-20 자임워크스 인코포레이티드 Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3223845A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AU2016280102A1 (en) 2015-06-16 2017-12-07 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP2018528979A (en) 2015-07-24 2018-10-04 ペティット,ジョージ,ロバート Quinstatin compound
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
JP6486316B2 (en) * 2015-11-03 2019-03-20 財團法人工業技術研究院Industrial Technology Research Institute Antibody-drug conjugate (ADC) and method for forming the same
JP2019500862A (en) 2015-12-07 2019-01-17 ゼンコア インコーポレイテッド Heterodimeric antibodies that bind to CD3 and PSMA
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
EP3465221A1 (en) 2016-05-27 2019-04-10 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
US20180154018A1 (en) 2016-11-23 2018-06-07 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
CN110312730A (en) * 2017-04-19 2019-10-08 四川科伦博泰生物医药股份有限公司 Cytotoxin and conjugate, its Use and preparation method
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
TW201905037A (en) 2017-06-22 2019-02-01 美商梅爾莎納醫療公司 Drug-carrying polymer scaffold protein and process for producing the polymeric drug conjugate
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
DK0598129T3 (en) * 1991-08-09 2000-07-03 Teikoku Hormone Mfg Co Ltd New tetrapeptide derivatives
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) * 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) * 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JP3469580B2 (en) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 The novel peptide derivatives
WO1996033212A1 (en) * 1995-04-21 1996-10-24 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents

Also Published As

Publication number Publication date
ES2233928T3 (en) 2005-06-16
DE69434136T2 (en) 2005-12-01
KR960704919A (en) 1996-10-09
DE69434136D1 (en) 2004-12-23
WO1995009864A1 (en) 1995-04-13
AU7666194A (en) 1995-05-01
EP0731106B1 (en) 2004-11-17
CA2173150C (en) 2004-11-30
EP0731106A1 (en) 1996-09-11
AU689131B2 (en) 1998-03-26
SG44794A1 (en) 1997-12-19
JP3469580B2 (en) 2003-11-25
US6124431A (en) 2000-09-26
US5767237A (en) 1998-06-16
CA2173150A1 (en) 1995-04-13
EP0731106A4 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
DE69421418T2 (en) Fliessbettpolymerisationsreaktor
DE69429061D1 (en) Superskalarmikroprozessoren
DE69408738D1 (en) Toneraggregierungsverfahren
DE69425198D1 (en) Zweiwegkabelfernsehsystem
DE69407573T2 (en) Fluorsiloxanhydrogele
DE69434145D1 (en) Wirbeldistraktor
DE69400714D1 (en) Nähfadenankeremführungssystem
DE69427973T2 (en) Schuhsohlekomponent
DE69425966D1 (en) Apheresisgerät
DE69425879D1 (en) Taxolformulierung
DE69411848D1 (en) Furanylinsektizide
DE69400639T2 (en) Rehydratationsgetraenk
DE69419615T2 (en) Sprachaktivitaetsdetektor
DE69433968D1 (en) Kommunikationsnetwerkverwaltung
DE69416717T2 (en) Bewegtbildkoder and -dekoder
DE69421125D1 (en) Rechnersystemsintegrierung
DE69427265T2 (en) Superskalarbefehlsdekoder
DE69401023D1 (en) Dampfdränageeinrichtung
DE69432495T2 (en) Fibrinogenextraktion
DE69427306D1 (en) Wasserundurchlässigkeitsmembran
DE69421639T2 (en) Aza-Zyklohexapeptide
DE69408074D1 (en) Einhebelkartuscheventil
DE69413122D1 (en) Invertemulsionsbohrspülungen
DE69404575D1 (en) Kautschukleitwand
DE69430989T2 (en) Stromleitungskommunikationsanalysator

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0731106

Country of ref document: EP

REN Ceased due to non-payment of the annual fee